Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) Patients

NCT06379360 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

77

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: Hypomethylating agent, Azacitidine or Decitabine

Sponsor

The First Affiliated Hospital of Soochow University